CureVac (CVAC) Competitors $3.22 -0.04 (-1.07%) As of 02:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CVAC vs. OGN, MOR, SWTX, CRNX, CPRX, PTGX, VKTX, SRRK, IMVT, and HCMShould you be buying CureVac stock or one of its competitors? The main competitors of CureVac include Organon & Co. (OGN), MorphoSys (MOR), SpringWorks Therapeutics (SWTX), Crinetics Pharmaceuticals (CRNX), Catalyst Pharmaceuticals (CPRX), Protagonist Therapeutics (PTGX), Viking Therapeutics (VKTX), Scholar Rock (SRRK), Immunovant (IMVT), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. CureVac vs. Organon & Co. MorphoSys SpringWorks Therapeutics Crinetics Pharmaceuticals Catalyst Pharmaceuticals Protagonist Therapeutics Viking Therapeutics Scholar Rock Immunovant HUTCHMED Organon & Co. (NYSE:OGN) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, community ranking, valuation, risk and institutional ownership. Which has more risk & volatility, OGN or CVAC? Organon & Co. has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, CureVac has a beta of 2.48, indicating that its share price is 148% more volatile than the S&P 500. Does the MarketBeat Community favor OGN or CVAC? CureVac received 8 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 55.32% of users gave CureVac an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote. CompanyUnderperformOutperformOrganon & Co.Outperform Votes1833.33% Underperform Votes3666.67% CureVacOutperform Votes2655.32% Underperform Votes2144.68% Is OGN or CVAC more profitable? CureVac has a net margin of 20.72% compared to Organon & Co.'s net margin of 13.49%. Organon & Co.'s return on equity of 431.62% beat CureVac's return on equity.Company Net Margins Return on Equity Return on Assets Organon & Co.13.49% 431.62% 8.03% CureVac 20.72%21.98%15.72% Does the media favor OGN or CVAC? In the previous week, Organon & Co. had 11 more articles in the media than CureVac. MarketBeat recorded 14 mentions for Organon & Co. and 3 mentions for CureVac. Organon & Co.'s average media sentiment score of 1.17 beat CureVac's score of 0.32 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive CureVac 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend OGN or CVAC? Organon & Co. presently has a consensus price target of $20.60, suggesting a potential upside of 70.04%. CureVac has a consensus price target of $16.00, suggesting a potential upside of 390.80%. Given CureVac's stronger consensus rating and higher possible upside, analysts plainly believe CureVac is more favorable than Organon & Co..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.43CureVac 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, OGN or CVAC? Organon & Co. has higher revenue and earnings than CureVac. Organon & Co. is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganon & Co.$6.40B0.49$864M$3.333.64CureVac$535.18M1.37-$281.58M$0.823.98 Do institutionals & insiders hold more shares of OGN or CVAC? 77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 1.4% of Organon & Co. shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryCureVac beats Organon & Co. on 10 of the 19 factors compared between the two stocks. Get CureVac News Delivered to You Automatically Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVAC vs. The Competition Export to ExcelMetricCureVacPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$731.34M$6.59B$5.41B$7.70BDividend YieldN/A3.21%5.44%4.33%P/E Ratio5.937.0522.2418.31Price / Sales1.37273.45397.24107.04Price / CashN/A65.6738.2034.62Price / Book1.306.506.844.25Net Income-$281.58M$142.50M$3.20B$247.51M7 Day Performance4.49%8.32%5.79%6.86%1 Month Performance12.03%-5.61%-4.29%-2.95%1 Year Performance41.13%0.11%17.99%5.17% CureVac Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVACCureVac3.574 of 5 stars$3.23-1.1%$16.00+396.1%+29.9%$723.49M$535.18M5.86880Gap UpOGNOrganon & Co.4.8629 of 5 stars$11.29+1.0%$20.60+82.5%-35.2%$2.91B$6.40B3.3910,000Upcoming EarningsPositive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SWTXSpringWorks Therapeutics2.1983 of 5 stars$37.46+2.7%$73.20+95.4%+3.6%$2.81B$191.59M-10.76230Upcoming EarningsNews CoverageCRNXCrinetics Pharmaceuticals3.5772 of 5 stars$29.78+2.3%$73.00+145.1%-22.9%$2.77B$1.04M-7.98210Positive NewsCPRXCatalyst Pharmaceuticals4.6332 of 5 stars$22.80+3.4%$32.29+41.6%+53.4%$2.77B$491.73M19.3280Positive NewsPTGXProtagonist Therapeutics3.7781 of 5 stars$45.03+5.7%$65.44+45.3%+74.5%$2.76B$434.43M16.93120News CoveragePositive NewsVKTXViking Therapeutics4.2022 of 5 stars$24.57+10.6%$89.75+265.3%-60.6%$2.76BN/A-24.5720Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap DownHigh Trading VolumeSRRKScholar Rock4.074 of 5 stars$28.93+3.3%$42.67+47.5%+144.0%$2.74B$33.19M-12.31140News CoveragePositive NewsIMVTImmunovant1.9669 of 5 stars$15.43+5.1%$41.00+165.7%-47.7%$2.62BN/A-5.89120Analyst ForecastNews CoverageHCMHUTCHMED2.0777 of 5 stars$14.89+8.5%$19.00+27.6%-14.5%$2.60B$630.20M0.001,988News CoverageGap Down Related Companies and Tools Related Companies OGN Competitors MOR Competitors SWTX Competitors CRNX Competitors CPRX Competitors PTGX Competitors VKTX Competitors SRRK Competitors IMVT Competitors HCM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CVAC) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CVAC Stock Free CVAC Stock Alerts